-
公开(公告)号：KR1020090090946A
公开(公告)日：2009-08-26
申请号：KR1020080016523
申请日：2008-02-22
Applicant: 전남대학교산학협력단
IPC: A61K39/395 , A61K38/00 , A61P35/00
CPC classification number: A61K39/39566 , A61K38/00 , Y10S514/885
Abstract: A composition for preventing and treating cervical cancer, which comprises lymphotoxin alpha/beta complex (LTalpha/beta) or lymphotoxin beta receptor (LTbeta-R) binding agent is provided to use an agent for preventing or treating cervical cancer by inducing the mucosa immune response. A composition for preventing and treating cervical cancer comprises limphotoxin alpha/beta complex or limphotoxin beta receptor binding agent as an active ingredient. The lymphotoxin alpha/beta complex is a surface lymphotoxin alpha/beta complex or recombinant soluble lymphotoxin alpha/beta complex. The lymphotoxin beta receptor is an antibody to lymphotoxin beta receptor. The antigen is polyclonal antibody or monoclonal antibody.
Abstract translation: 提供了一种用于预防和治疗宫颈癌的组合物，其包括淋巴毒素α/β复合物（LTα/β）或淋巴毒素β受体（LTbeta-R）结合剂，用于通过诱导粘膜免疫应答来预防或治疗宫颈癌 。 用于预防和治疗宫颈癌的组合物包含角光素α/β复合物或角叉松素β受体结合剂作为活性成分。 淋巴毒素α/β复合物是表面淋巴毒素α/β复合物或重组可溶性淋巴毒素α/β复合物。 淋巴毒素β受体是淋巴毒素β受体的抗体。 抗原是多克隆抗体或单克隆抗体。
-
Patent Agency Ranking2.发明授权
公开(公告)号：KR100960684B1
公开(公告)日：2010-05-31
申请号：KR1020080016505
申请日：2008-02-22
Applicant: 전남대학교산학협력단
CPC classification number: C07K14/705 , A01K67/0275 , A01K2217/052 , A01K2227/105 , A01K2267/0331 , A61K48/00 , C12N15/8509
Abstract: 본 발명은 TREM-2(Triggering Receptor Expressed on Myeloid cells-2) 유전자 또는 단백질을 포함하는 GA733-2 항원의 발현 억제 또는 검출용 조성물 및 방법, 및 이를 포함하는 형질전환 동물, 특히 형질전환 마우스 및 이의 사용방법에 관한 것으로서, 암, 특히 대장암의 원인 규명은 물론 그의 진단, 특히 조기진단 및 치료제 개발에 크게 기여할 수 있다.
TREM-2, GA733-2, 암, 대장암, 형질전환, 동물 모델, 마우스-
公开(公告)号：KR100967623B1
公开(公告)日：2010-07-05
申请号：KR1020080016523
申请日：2008-02-22
Applicant: 전남대학교산학협력단
IPC: A61K39/395 , A61K38/00 , A61P35/00
Abstract: 본 발명은 유효성분으로서 림포톡신 α/β 복합체(Lymphotoxin α/β Complex, LTα/β) 또는 림포톡신 β 수용체(Lymphotoxin β receptor, LTβ-R) 결합제를 포함하는, 자궁경부암 예방 또는 치료용 조성물에 관한 것으로서, 점막면역 반응을 효과적으로 유도함으로써 자궁경부암의 예방 또는 치료제로 유용하게 이용될 수 있다.
림포톡신, 림포톡신 α/β 복합체, LTα/β, 림포톡신 β 수용체, LTβ-R, 점막면역, 인유두종바이러스, HPV, E6, 자궁경부암-
公开(公告)号：KR1020090090952A
公开(公告)日：2009-08-26
申请号：KR1020080016531
申请日：2008-02-22
Applicant: 전남대학교산학협력단
IPC: A61K39/395 , A61K38/00
CPC classification number: A61K38/44 , A61K38/005 , A61K38/1774 , A61K39/395 , C12N15/62 , Y10S514/886
Abstract: A composition for regulating or detecting gamma-delta T cell or cytokines secreted by the gamma-delta T cell, which contains Axl receptor tyrosine kinase, its ligand or inhibitor is provided to regulate gamma-delta T cell and prevent or treat inflammatory bowl diseases (IBD). A composition for regulating gamma-delta T cell or a cytokine which is secreted by the gamma-delta T cell comprises an Axl receptor tyrosine kinase, its ligand or its inhibitor as an active ingredient. The composition is used for preventing and treating inflammatory bowel disease. A method for screening an agent for preventing and treating inflammatory bowel disease comprises: a step of adding a test compound in Axl receptor tyrosine kinase, its ligand or inhibitor; and a step of researching the influence of test compound on the expression or activation of Axl receptor tyrosine kinase, gamma-delta T cell, or cytokine secreted by the gamma-delta T cell.
Abstract translation: 提供用于调节或检测由含有Ax1受体酪氨酸激酶，其配体或抑制剂的γ-δT细胞分泌的γ-δT细胞或细胞因子的组合物，以调节γ-δT细胞并预防或治疗炎性碗疾病（ IBD）。 用于调节由γ-δT细胞分泌的γ-δT细胞或细胞因子的组合物包含Ax1受体酪氨酸激酶，其配体或其抑制剂作为活性成分。 该组合物用于预防和治疗炎症性肠病。 用于筛选用于预防和治疗炎症性肠病的药剂的方法包括：在Ax1受体酪氨酸激酶，其配体或抑制剂中加入测试化合物的步骤; 以及研究化合物对由γ-δT细胞分泌的Axl受体酪氨酸激酶，γ-δT细胞或细胞因子的表达或活化的影响的步骤。
-
公开(公告)号：KR1020090090944A
公开(公告)日：2009-08-26
申请号：KR1020080016520
申请日：2008-02-22
Applicant: 전남대학교산학협력단
CPC classification number: A61K48/00 , A61K2039/585 , C12N9/12
Abstract: A method for screening therapeutic agent or suppressing tumor by regulating Axl signal is provided to increase the sensitivity of natural killer cell by the expression of LIGHT gene and induce apoptosis of tumor cell. A composition for suppressing tumor comprises LIGHT (lymphotoxin-like inducible protein that competes with glycoprotein D for binding herpesvirus entry mediator on T cells) (TNFSF14) or its activator as an active ingredient. The activator is Axl receptor tyrosine kinase or its ligand. The Axl ligand is an antibody to Axl antibody, gamma-carboxylated Gas-6(growth-arrest specific gene 6) or protein S. The tumor is lymphatic tumor. A method for screening agent for suppressing or treating tumor comprises: a step of adding a test compound to a LIGHT (TNFSF14) or its activator; and a step of researching the influence of the test compound on the expression or activation of LIGHT or its activator.
Abstract translation: 提供通过调节Axl信号筛选治疗剂或抑制肿瘤的方法，以通过LIGHT基因的表达增加自然杀伤细胞的敏感性并诱导肿瘤细胞凋亡。 用于抑制肿瘤的组合物包括LIGHT（与蛋白D竞争结合于T细胞上的疱疹病毒进入介导蛋白的竞争性淋巴毒素样诱导蛋白）（TNFSF14）或其活化剂作为活性成分。 活化剂是Axl受体酪氨酸激酶或其配体。 Axl配体是Ax1抗体，γ-羧化气体-6（生长停滞特异性基因6）或蛋白S的抗体。肿瘤是淋巴瘤。 用于抑制或治疗肿瘤的筛选剂的方法包括：将测试化合物加入到LIGHT（TNFSF14）或其活化剂中的步骤; 以及研究化合物对LIGHT或其活化剂表达或活化的影响的一个步骤。
-
6.发明公开
公开(公告)号：KR1020090090935A
公开(公告)日：2009-08-26
申请号：KR1020080016505
申请日：2008-02-22
Applicant: 전남대학교산학협력단
CPC classification number: C07K14/705 , A01K67/0275 , A01K2217/052 , A01K2227/105 , A01K2267/0331 , A61K48/00 , C12N15/8509
Abstract: A composition for detecting or suppressing the expression of GA733-2 antigen containing TREM-2 (Triggering Receptor Expressed on Myeloid cells-2) gene or protein is provided to use in the investigation of cancer cause, early diagnosis of cancer and development of therapeutic agent. A composition for suppressing the expression of GA733-2 antigen comprises a TREM-2 (Triggering Receptor Expressed on Myeloid cells-2) gene or protein as an active ingredient. The expression of GA733-2 antigen in a biological sample is suppressed by adding TREM-2 gene or protein. A method for screening an agent for suppressing and treating cancer comprises: a step of adding a TREM-2 gene or protein or candidate drug which suppresses or treat cancer into transgenic animal which is transformed with TREM-2 gene; and a step of researching the influence of the candidate drug on the expression or activation of TREM-2 or GA733-2. The cancer is colon cancer.
Abstract translation: 提供了用于检测或抑制含有TREM-2（触发受体表达于骨髓细胞-2）基因或蛋白质的GA733-2抗原表达的组合物用于癌症原因的调查，癌症的早期诊断和治疗剂的发展 。 用于抑制GA733-2抗原表达的组合物包含TREM-2（以骨髓细胞-2表达的触发受体）基因或蛋白质作为活性成分。 通过添加TREM-2基因或蛋白质抑制生物样品中GA733-2抗原的表达。 用于筛选抑制和治疗癌症的药剂的方法包括：向TREM-2基因转化的转基因动物中加入抑制或治疗癌症的TREM-2基因或蛋白质或候选药物的步骤; 研究候选药物对TREM-2或GA733-2表达或激活的影响的一个步骤。 癌症是结肠癌。
-
-
-
-
-
Search Results
6
records
(took 0.02 seconds)
